Biotech Stocks Set to Breakout
HENDERSON, NV / ACCESSWIRE / December 20, 2018 / Here is a list of several Biotech companies with announcements that could move their markets in the coming sessions.
We are highlighting: Endonovo Therapeutics, Inc. (ENDV), Cronos Group, Inc. (CRON), Novavax, Inc. (NVAX), Celgene Corporation (CELG), and Gilead Sciences, Inc. (GILD).
According to the FDA, more than 72,000 people died from drug overdoses in 2017, including overdoses due to illicit drugs and prescription opioids. Biotech and CBD companies are both working on different solutions to this dire issue. One of which has just announced something that makes us even more intrigued than we already were. Endonovo Therapeutics, Inc. (ENDV) (Market Cap: $7.903M, Share Price: $0.0200), a commercial-stage developer of non-invasive wearable Electroceuticals™ Therapies, has developed a therapy that could help lessen the pain without the kinds of side effects many other opioid alternatives have. Their non-invasive easy to use ORTHOHALO™ device delivers targeted Pulsed ElectroMagnetic Field (tPEMF) therapies to reduce pain and enhance post-surgical recovery, naturally. Its patented non-pharmacologic process uses proprietary technology to reduce pain, swelling, and inflammation.
The announcement that peaked our interest is that ENDV has formed a partnership with US Authentic Trading Company (USAT) to act as the exclusive partner to assist with facilitating a relationship between the Company and China. China has been dealing with opioids since the 1600s, all the way back to the Opium wars. This market added to the already robust US market makes ENDV one of the most enticing opioid alternative plays on the market.
Finally, the company just announced the allowance for the patent application entitled Devices And Method For Treatment Of Degenerative Joint Diseases with Electromagnetic Fields by the U.S. Patent and Trademark Office. Endonovo will be including this technology under its WOUNDPULSE™ brand.
____
Cronos Group, Inc. (CRON) (Market Cap: $2.014B, Share Price: $11.17) has been on fire the company announced that leading tobacco company, Altria Group, Inc. MO will make an approximately C$2.4-billion equity investment in the company.
____
Novavax, Inc. (NVAX) (Market Cap: $825.956M, Share Price: $2.16) recently announced several key management promotions while the company pushes its lead clinical programs into commercial stage. The company is pushing their ResVax and NanoFlu programs towards licensure.
____
Celgene Corporation (CELG) (Market Cap: $45.857B, Share Price: $65.58) will present a business update and provide 2019 financial guidance at the 37th Annual J.P. Morgan Healthcare Conference on January 7, 2019 at 7:30 a.m. PT/ 10:30 a.m. ET.
____
Gilead Sciences, Inc. (GILD) (Market Cap: $83.05B, Share Price: $64.20) announced that Roche's O'Day will become CEO and chairman effective March 1, 2019, replacing John Milligan, who previously said he would step down from his role as president and CEO and as a board member at the end of 2018. O'Day is currently CEO of Roche Pharmaceuticals, a position he has held since 2012. O'Day joined Roche back in 1987, taking on various roles in the U.S. before moving to Roche headquarters in Switzerland in 1998 and later to Japan, Denmark and eventually back to California.
Legal Disclaimer:
This article was written by Regal Consulting, LLC ("Regal Consulting"). Regal consulting has agreed to receive 3 million restricted 144 shares as a signing bonus, and additionally receive $4,000 cash per month, and 1 million restricted 144 shares per month starting 8/23/18, this is a twelve-month agreement, and can be canceled at anytime by the issuer ENDV. All payments were made directly by Endonovo Therapeutics, Inc. to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to microcapspeculators.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. ENDV was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice.
http://www.regalconsultingllc.com/full legal disclaimer/
Microspeculators.com Full Legal Disclaimer Click Here.
Contact Information:
Company Name: Microcap Speculators
Contact Person: Media Manager
Email: info@microcapspeculators.com
Phone: 1-702-720-6310
Country: United States
Website: http://microcapspeculators.com/
SOURCE: Microcap Speculators
